Why the study?
SGLT2 inhibitors are now indicated for heart failure and CKD regardless of diabetes status, giving cardiologists and nephrologists an important role in initiating them, but their perspectives and safety monitoring practices needed exploration.
There is a reluctance among non-heart-failure cardiologists to prescribe SGLT2 inhibitors, highlighting the need for interdisciplinary collaboration and clear guidance to overcome the perception of these agents as solely diabetes drugs.
Answers are grounded in this paper and cite their sources.
Specialist perspectives on SGLT2i initiation and monitoring vary widely; leaves open optimal implementation strategies in HF and CKD.
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now indicated for heart failure and chronic kidney disease (CKD), irrespective of the presence of diabetes. Hence, cardiologists and nephrologists have an important role in initiating these drugs. AIMS: To explore cardiologists' and nephrologists' perspectives regarding initiating SGLT2i and their safety monitoring practices when initiating SGLT2i. METHODS: Purposive and snowball approaches were used to recruit participants working in diverse areas in New South Wales, Australia. Semi-structured interviews were conducted with 12 cardiologists and 12 nephrologists. Interviews were conducted until thematic saturation was reached. Emergent themes were identified from transcripts. An iterative general inductive approach was used for data analysis. RESULTS: There was a reluctance amongst most non-heart-failure subspecialist cardiologists to initiate SGLT2i. Reasons included the perception of SGLT2i as diabetes drugs, concern about side effects, lack of experience and issues with follow-up. In contrast, nephrologists reported feeling confident to initiate SGLT2i. Nephrologists varied in their opinions about the severity of CKD at which SGLT2i initiation was reasonable and monitoring of renal function following initiation. Government subsidisation was an important factor in the decision to prescribe SGLT2i to people without diabetes. CONCLUSIONS: Our findings highlight the complex transition from the perception of SGLT2i as diabetes drugs to cardiometabolic and reno-protective agents. Interdisciplinary collaboration may enable greater confidence amongst specialists to initiate SGLT2i, including in patients with CKD. Additionally, there is a need for clear and detailed guidance about SGLT2i prescription in patients with renal dysfunction and renal function monitoring following SGLT2i initiation.
No takes yet. Share an insight, caveat, or question.
Milder et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: